Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94542Research ArticleLower urinary tract symptoms: drug treatment accumulation phase symptoms (clinical lecture)RasnerP. Idr.rasner@gmail.comPushkarD. Yu-A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation15072016187303628122021Copyright © 2016, Consilium Medicum2016In recent years, there has been a trend in which the basis for selection of the optimal treatment strategy is the analysis of the specific complaints of the patient, taking into account their individual expectations from this treatment. The introduction of the wide practice of some elements of artificial intelligence, such as validated questionnaires, expert systems and nomograms, greatly facilitates the diagnosis. Statistical analysis of the requirements of patient complaints indicates obviously a greater prevalence of the accumulation phase problems, which is probably a consequence of the fact that many of the patients overactive bladder symptoms is present 8-16% of the adult population in Europe and 60% of patients with severe bladder outlet obstruction. Drug therapy of lower urinary tract symptoms (LUTS) accumulation phase may be carried out as monotherapy, or in combination stepwise prescribing a format with a different mechanism of action. The basis of such therapy are .-blockers, anticholinergics M and recently appeared the .3-adrenergic receptor agonists. Such a wide variety of treatment options allows an individual approach to each patient and provides a high probability of getting rid of LUTS.dysurialower urinary tract symptomsprostate diseaseoveractive bladderрасстройство мочеиспусканиясимптомы нижних мочевых путейзаболевания предстательной железыгиперактивный мочевой пузырь[EAU Guidelines on the Assessment of Non - neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 2015; 67 (Issue 6): 1099-109.][Barry M.J, Jr. Fowler F.J, O'Leary M.P et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee ofthe American Urological Association. J Urol 1992; 148: 1549-57.][Van Venrooij G.E, Eckhardt M.D, Gisholf K.W, Boon T.A. Data from frequency - volume charts versus symptom scores and quality of life score in menwith lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2001; 39: 42-7.][Irwin D.E, Milsom I, Hunskaar S et al. Population - based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306-14.][Peters T.J, Donovan J.L, Kay H.E et al. The ICS-“BPH” Study: the bothersomeness of urinary symptoms. J Urol 1997; 157 (3): 885-9.][Van Exel N.J, Koopmanschap M.A, McDonnell J et al. TRIUMPH Pan - European Expert Panel Medical consumption and costs during a one - year follow - up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. Eur Urol 2006; 49 (1): 92-102.][Раснер П.И., Пушкарь Д.Ю. Лечение симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы: современные международные стандарты//Справочник поликлинического врача. 2015; 10: 20-6.][Isaacs J.T. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3 (Suppl.): 1-7.][Flanigan R.C, Reda D.J, Wasson J.H et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH: a Department of Veterans Affairs cooperative study. J Urol 1998; 160 (1): 12-6.][Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64 (6): 1081-8.][Давидов М.И., Локшин К.Л., Горбунова И.С. Частота острой задержки мочи у больных аденомой предстательной железы при 8-летнем лечении тамсулозином. Урология. 2015; 2: 74-81.][Kaplan S.A. Medical Therapy for Benign Prostatic Hyperplasia: New Terminology, New Concepts, Better Choices. Rev Urol 2006; 8 (1): 14-22.][Вишневский А.Е. Роль гипоксии детрузора в патогенезе расстройств мочеиспускания у больных доброкачественной гипеплазией предстательной железы и обоснование методов их консервативного лечения. Автореф. дис. … канд. мед. наук. М., 1998.][Кривобородов Г.Г., Школьников М.Е., Ефремов Н.С. и др. Холинолитики в лечении симптомов накопления мочевого пузыря у мужчин с доброкачественной гиперплазией предстательной железы. Эффективная фармакотерапия. Урология и Нефрология. 2011; 3: 26-8.][Michel M.C, Schneider T, Krege S et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168 (3): 1027-31.][Stenzelius K, Mattiasson A, Hallberg I.R, Westergren A. Symptoms of urinary and faecal incontinence among men and women 75+ in relations to health complaints and quality of life. Neurourol Urodynam 2004; 23: 211-22.][Борисов В.В. Гиперактивный мочевой пузырь: эффективное лечение. Consilium Medicum. 2014; 16 (7): 22-8.][Gravas S, Bachmann A, Descazeaud A et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). http://www.uroweb.org/gls/pdf/Non-Neurogenic%20Male%20LUTS_(2705).pdf][Gong М, Dong W, Huang G et al. Tamsulosin Combined Solifenacin versus Tamsulosin Monotherapy on Male Lower Urinary Tract Symptoms: A Meta - analysis. Curr Med Res Opin 2015 20; 31 (9): 1781-92.][Drake M.J, Chapple C, Sokol R et al. NEPTUNE Study Group. Long - term safety and efficacy of single - tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open - label extension. Eur Urol 2015; 67 (2): 262-70.][Witte L.P, Mulder W.M, De la Rosette J.J et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19 (1): 13-9.][Zinner N, Noe L, Rasouliyan L et al. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 2008.][Abrams P, Kaplan S, De Koning Gans H.J, Millard R. Safety and tolerability of tolterodine for treatment of overactive bladder and coexisting benign prostatic obstruction: a prospective randomized, controlled multicenter study. J Urol 2006; 169: 2253-6.][Athanasopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha - blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-6.][Kaplan S.A, Walmsley K, Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-6.][Lee J.Y, Kim H.W, Lee S.J et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20.][Robinson D, Thiagamoorthy G, Cardozo L. A drug safety evaluation of mirabegron in the management of overactive bladder. Exp Opin Drug Saf 2016; 15 (5): 689-96. Doi: 10.1517/14740338.2016.1165663. Epub 2016 Apr 21.][Nitti V.W, Auerbach S, Martin N et al: Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013; 189: 1388.][Khullar V, Amarenco G, Angulo J.C et al. Efficacy and tolerability of mirabegron, a.(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013; 63: 283.][Chapple C.R, Kaplan S.A, Mitcheson D et al. Randomized Double - blind, active - controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a.(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296.]